Literature DB >> 15038986

A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction.

Helen Moore1, Natasha K Li.   

Abstract

In this paper, we propose and analyse a mathematical model for chronic myelogenous leukemia (CML), a cancer of the blood. We model the interaction between naive T cells, effector T cells, and CML cancer cells in the body, using a system of ordinary differential equations which gives rates of change of the three cell populations. One of the difficulties in modeling CML is the scarcity of experimental data which can be used to estimate parameters values. To compensate for the resulting uncertainties, we use Latin hypercube sampling (LHS) on large ranges of possible parameter values in our analysis. A major goal of this work is the determination of parameters which play a critical role in remission or clearance of the cancer in the model. Our analysis examines 12 parameters, and identifies two of these, the growth and death rates of CML, as critical to the outcome of the system. Our results indicate that the most promising research avenues for treatments of CML should be those that affect these two significant parameters (CML growth and death rates), while altering the other parameters should have little effect on the outcome.

Entities:  

Mesh:

Year:  2004        PMID: 15038986     DOI: 10.1016/j.jtbi.2003.11.024

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  20 in total

1.  T cell state transition produces an emergent change detector.

Authors:  Peter S Kim; Peter P Lee
Journal:  J Theor Biol       Date:  2011-01-27       Impact factor: 2.691

2.  Optimization of combination therapy for chronic myeloid leukemia with dosing constraints.

Authors:  Helen Moore; Lewis Strauss; Urszula Ledzewicz
Journal:  J Math Biol       Date:  2018-07-10       Impact factor: 2.259

3.  A multicellular basis for the origination of blast crisis in chronic myeloid leukemia.

Authors:  Rainer K Sachs; Kerstin Johnsson; Philip Hahnfeldt; Janet Luo; Allen Chen; Lynn Hlatky
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

4.  Dependence of CD8 T Cell Response upon Antigen Load During Primary Infection : Analysis of Data from Yellow Fever Vaccination.

Authors:  James R Moore; Hasan Ahmed; Don McGuire; Rama Akondy; Rafi Ahmed; Rustom Antia
Journal:  Bull Math Biol       Date:  2019-06-04       Impact factor: 1.758

5.  Global dynamics of hematopoietic stem cells and differentiated cells in a chronic myeloid leukemia model.

Authors:  Bedr'eddine Aïnseba; Chahrazed Benosman
Journal:  J Math Biol       Date:  2010-08-18       Impact factor: 2.259

6.  The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia.

Authors:  Adam L MacLean; Sarah Filippi; Michael P H Stumpf
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

7.  Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction.

Authors:  Bernhard Mlecnik; Fatima Sanchez-Cabo; Pornpimol Charoentong; Gabriela Bindea; Franck Pagès; Anne Berger; Jerome Galon; Zlatko Trajanoski
Journal:  BMC Genomics       Date:  2010-02-10       Impact factor: 3.969

8.  Optimal sliding mode control of drug delivery in cancerous tumour chemotherapy considering the obesity effects.

Authors:  Pariya Khalili; Ramin Vatankhah; Sajjad Taghvaei
Journal:  IET Syst Biol       Date:  2018-08       Impact factor: 1.615

9.  Mathematical Modelling Based on In Vivo Imaging Suggests CD137-Stimulated Cytotoxic T Lymphocytes Exert Superior Tumour Control Due to an Enhanced Antimitotic Effect on Tumour Cells.

Authors:  Richard J Beck; Bettina Weigelin; Joost B Beltman
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

10.  Cancer immunoediting: A game theoretical approach.

Authors:  Fatemeh Tavakoli; Javad Salimi Sartakhti; Mohammad Hossein Manshaei; David Basanta
Journal:  In Silico Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.